Patents by Inventor Toomas Mitt

Toomas Mitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7655689
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: February 2, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7517904
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: April 14, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION
    Publication number: 20080214643
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 21, 2008
    Publication date: September 4, 2008
    Inventors: Mark E. Salvati, James Aaron Balog, Toomas Mitt
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7141578
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20060264459
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 15, 2006
    Publication date: November 23, 2006
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20060223832
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 12, 2004
    Publication date: October 5, 2006
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20050272799
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: July 7, 2005
    Publication date: December 8, 2005
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
    Patent number: 6953679
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: October 11, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, Toomas Mitt, Ramesh N. Patel, Ronald L. Hanson, David Brzozowski, Animesh Goswami, Linda Nga Hoong Chu, Wen-sen Li, James H. Simpson, Michael J. Totleben, Weixuan He
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20050192253
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 25, 2004
    Publication date: September 1, 2005
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
    Publication number: 20050119228
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 19, 2001
    Publication date: June 2, 2005
    Inventors: Mark Salvati, Toomas Mitt, Ramesh Patel, Ronald Hanson, David Brzozowski, Animesh Goswami, Linda Chu, Wen-sen Li, James Simpson, Michael Totleben, Weixuan He
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20040077605
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 18, 2002
    Publication date: April 22, 2004
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Amino-substituted compounds useful as inhibitors of IMPDH enzyme
    Patent number: 6617323
    Abstract: The present invention discloses compounds useful in treating or preventing IMPDH-associated disorders, such as transplant rejection and autoimmune diseases, having the formula (I), wherein X is —C(O)—, —C(S)—, or —S(O)2—; A is an optionally-substituted saturated or unsaturated monocyclic or bicyclic ring; B is a saturated or unsaturated monocyclic or bicyclic ring system having at least one substituent Q which is selected from R7 and R8; R7 is selected from (C0-C6)alkyl, (C2-C6)alkenyl and (C2-C6)alkynyl and R7 is substituted with R8 is selected from (C0-C6)alkyl, (C2-C6)alkenyl and (C2-C6)alkynyl and R8 is substituted with and Z1 through Z5 are as defined in the specification.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: September 9, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Edwin J. Iwanowicz, Katerina Leftheris, Chunjian Liu, Toomas Mitt, Scott H. Watterson
  • Amino-substituted compounds useful as inhibitors of impdh enzyme
    Publication number: 20020183315
    Abstract: The present invention discloses compounds useful in treating or preventing IMPDH-associated disorders, such as transplant rejection and autoimmune diseases, having the formula (I), 1
    Type: Application
    Filed: May 23, 2002
    Publication date: December 5, 2002
    Inventors: Edwin J. Iwanowicz, Katerina Leftheris, Chunjian Liu, Toomas Mitt, Scott H. Watterson
  • Inhibitors of farnesyl protein transferase
    Patent number: 6455523
    Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras ocogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof inhibit farnesyl protein transferase which is an enzyme involved in ras oncogene expression.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: September 24, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Charles Z. Ding, Soong-Hoon Kim, John T. Hunt, Toomas Mitt, Rajeev Bhide, Katerina Leftheris
  • Inhibitors of IMPDH enzyme
    Patent number: 6420403
    Abstract: The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH-associated disorders, such as transplant rejection and autoimmune diseases.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: July 16, 2002
    Inventors: Edwin J. Iwanowicz, T. G. Murali Dhar, Katerina Leftheris, Chunjian Liu, Toomas Mitt, Scott H. Watterson, Joel C. Barrish
  • Inhibitors of farnesyl protein transferase
    Patent number: 6011029
    Abstract: The present invention comprises benzodiazepine compounds having farnesyl transferase inhibitory activity.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: January 4, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Charles Z. Ding, Soong-Hoon Kim, John T. Hunt, Toomas Mitt, Rajeev Bhide, Katerina Leftheris
  • Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process
    Patent number: 5874578
    Abstract: A purine salt of the formula ##STR1## wherein Y.sub.1 is chloro, bromo, or iodo, and R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently selected from alkyl and substituted alkyl is reacted with the compound of the formulaZ.sub.1 --Xto yield the purine of the formula ##STR2## wherein x is a leaving group, and Z.sub.1 is a protected form of the carbohydrate surrogate Z.
    Type: Grant
    Filed: January 25, 1993
    Date of Patent: February 23, 1999
    Assignee: Bristol-Myers Squibb
    Inventors: Janak Singh, Gregory S. Bisacchi, Jollie D. Godfrey, Jr., Toomas Mitt, Richard H. Mueller, Robert Zahler, Thomas P. Kissick
  • Purinyl salts useful for preparing guanine containing antiviral agents
    Patent number: 5608064
    Abstract: A purine salt of the formula ##STR1## wherein Y.sub.1 is chloro, bromo, or iodo, and R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently selected from alkyl and substituted alkyl.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 4, 1997
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Janak Singh, Gregory S. Bisacchi, Jollie D. Godfrey, Jr., Toomas Mitt, Richard H. Mueller, Robert Zahler, Thomas P. Kissick
  • Intermediates for an optically active cyclobutane nucleoside
    Patent number: 5306837
    Abstract: Novel intermediates useful in the preparation of the optically active antiviral compound [1R-(1.alpha.,2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobut yl]-1,9-dihydro-6H-purin-6-one are described.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: April 26, 1994
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gregory S. Bisacchi, Toomas Mitt
  • Intermediates for the preparation of optically active cyclobutane nucleoside
    Patent number: 5256806
    Abstract: Novel intermediates useful in the preparation of the optically active antiviral compound [1R-(1.alpha.,2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobut yl]-1,9-dihydro-6H-purin-6-one are described.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: October 26, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gregory S. Bisacchi, Toomas Mitt